GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Forward PE Ratio

Galapagos NV (Galapagos NV) Forward PE Ratio : 0.00 (As of May. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Forward PE Ratio?

Galapagos NV's Forward PE Ratio for today is 0.00.

Galapagos NV's PE Ratio without NRI for today is 0.00.

Galapagos NV's PE Ratio for today is 8.40.


Galapagos NV Forward PE Ratio Historical Data

The historical data trend for Galapagos NV's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Forward PE Ratio Chart

Galapagos NV Annual Data
Trend 2019-10 2022-12 2023-11
Forward PE Ratio
172.41 84.75 97.09

Galapagos NV Quarterly Data
2022-09 2022-12 2023-03
Forward PE Ratio 81.97 84.75 84.03

Competitive Comparison of Galapagos NV's Forward PE Ratio

For the Biotechnology subindustry, Galapagos NV's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Forward PE Ratio falls into.



Galapagos NV Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Galapagos NV  (NAS:GLPG) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Galapagos NV Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.